Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine added to conventional treatment for treatment-resistant depression and suicidal risk
RBR-99z7jnqPhase 3Not yet recruiting
- Sponsor
- Hospital Universitário Walter Cantídio
- Start
- Feb 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine and lithium carbonate in treatment-resistant depression (TRD), bipolar disorder (BD) and Suicidality (6 arms), sponsored by Hospital Universitário Walter Cantídio. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ketaminelithium carbonate
03
Conditions
treatment-resistant depression (TRD)bipolar disorder (BD)Suicidality
Beyond the preview
Go deeper on RBR-99z7jnq.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-99z7jnq.